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Molecular targeted therapy (MTT), using chemicals of low 
molecular weight, monoclonal antibodies, and/or polypep-
tides to interfere with specific signaling pathways in cancer 
cells, causes inhibition of tumor progression. Clinical evi-
dence has demonstrated that MTT has promising potential 
in not only killing tumors but also inducing tumor cells to 
differentiate into normal cells, leading to cure of the patients. 
Furthermore, MTT leads to potent inhibition of oncogenic 
signals. The delay of tumor progression makes the patients 
“survive with tumor”. Thus, in the future it is possible that 
cancer becomes a chronic disease much like diabetes and 
hypertension. This article reviews the theory on molecular 
targeted therapy, its features and future direction, and con-
tributions in the field from Chinese scientists.  
1  The concept of molecular targeted therapy  
In the last two centuries, there were two leaps in the treat-
ment of malignant tumors. One was in 1890 when Halsted 
proposed the concept of radical surgery for cancer, and the 
other was in the 1970s when Fish integrated the chemical 
treatment with radical surgery (adjuvant chemotherapy or 
neoadjuvant chemotherapy). Since then, the treatment of 
malignant tumor did not have much development until the 
emergence of molecular targeted drugs. In the late 20th  
century, researchers began to study tumor in a system bio-
logical point of view and realized that tumor is a mul-
ti-factor participated, multi-step in development and sys-
temic disease. Mutation of oncogenes, missing of tumor 
suppressor genes or abnormal gene expressions often leads 
to genomic instability in tumor cells and further abnormal 
biological behaviors in tumor cells, such as (i) self-suffi- 
ciency in growth signals, (ii) insensitivity to growth inhibi-
tion signals, (iii) evading apoptosis, (iv) unlimited potential 
for replication, (v) angiogenesis, (vi) invasion and metasta-
sis, and (vii) immune escape. Molecular targeted therapy 
refers to the use of chemicals of low molecular weight, 
monoclonal antibodies, polypeptides and other substances 
to interfere with specific signaling pathways that regulate 
biological behaviors of tumor cells, thereby inhibiting tumor 
progression. Molecular targeted therapy is essentially dif-
ferent from traditional chemotherapy, in which small mo-
lecular compounds are used to directly damage DNA, im-
pede cell mitosis or induce cell death. The drawback is that 
chemotherapy lacks selectivity between normal cells and 
tumor cells. Drug toxicity and side effects limit the intensity 
and frequency of chemotherapy. It harms not only the func-
tion of vital organs such as heart, liver, lung, kidney, bone 
marrow, but also immune system, resulting in the loss of 
self-protective barriers to tumor. In addition, chemotherapy 
increases the instability of the tumor cell genome, which 
will precipitate the process for tumor cells to develop adap- 
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tation to chemotherapeutic drugs. Therefore, toxicity and 
side effects of chemotherapy and drug resistance may make 
it difficult for most patients to accomplish chemotherapy. In 
contrast, molecular targeted therapy targets abnormal sig-
naling pathways in tumor cells. With virtues of high selec-
tivity, low toxicity and high therapeutic index, molecular 
targeted therapy can be used for a long time, which then 
may help transform malignant tumors into a chronic disease 
similar to hypertension or diabetes.  
Starting from 1997 when the monoclonal antibody 
trastuzumab (Herceptin) and rituximab (MabThera) were 
approved for the treatment of metastatic breast cancer and 
diffuse large B-cell lymphoma, the history of molecular 
targeted therapy is merely longer than a decade. So far, 
more than ten kinds of molecular targeted drugs have been 
approved for the treatment of solid tumors, and some others 
for hematological malignancies. Patient survival time is the 
gold standard for evaluating drug efficacy. The value of 
molecular targeted therapy is demonstrated in two ways: on 
the one hand, through inducing tumor cell differentiation or 
combining with surgery, radiotherapy, chemotherapy and 
other treatment measures, molecular-targeted drugs are able 
to increase 5-year survival rate of patients with neoplasm, in 
other words, more patients will be cured. Examples are 
trans-retinoic acid (acute promyelocytic leukemia), 
trastuzumab (breast cancer), rituximab (lymphoma) and 
imatinib (gastrointestinal stromal tumors, chronic mye-
logenous leukemia), etc. On the other hand, by delaying 
tumor progression molecular targeted therapy will improve 
the quality of life of patients and extend their survival time. 
Examples are erlotinib (non-small cell lung cancer, pancre-
atic cancer), gefitinib (non-small cell lung cancer), temsiro-
limus (renal cell carcinoma), bevacizumab (colorectal can-
cer, non-small cell lung cancer, breast cancer and renal cell 
carcinoma), cetuximab (colorectal carcinoma, head and 
neck squamous cell carcinoma), apatinib (breast cancer) and 
sorafenil (renal cell carcinoma), sunitinib (renal cell carci-
noma, gastrointestinal stromal tumors), endostar (non-small 
cell lung cancer) and bortezomib (multiple myeloma) and so 
on. With the further research and development, the clinical 
value of molecular targeted therapy will be constantly en-
riched and expanded.  
2  Featured achievements of molecular targeted 
therapy  
2.1  Induction of tumor cells to differentiate into nor-
mal cells for curing the patients 
Compared with normal cells, tumor cells have one different 
yet important biological feature—poor differentiation, thus 
neoplasm is seen as a differentiation disorder or a dediffer-
entiation disease. Differentiation-induction is described as 
inducing redifferentiation of malignant cells into normal or 
nearly normal cells for making changes to their malignant 
biological behaviors, stopping their vicious hyperplasia, and 
ultimately leading to alleviation of malignant tumors or 
even cure of them without damaging normal cells. Com-
pared with traditional treatment choices of surgery, chemo-
therapy, radiotherapy and others based on the concept of 
“irreversible tumor cells”, differentiation-induction has 
opened up a new door for the treatment for malignant tu-
mors, with the example drug being trans-retinoic acid. 
Since1980, medical scientists in China, as Drs. Wang 
ZhenYi and Chen Zhu, have successfully developed retinoic 
acid (RA) which may induce tumor cells to differentiate 
into normal hematopoietic cells, with eastern philosophy’s 
concept of “Dayu’s method of controlling the flood instead 
of stopping the flood” as their guidance. It is a milestone for 
tumor differentiation-induction therapy and a model of tu-
mor targeted therapy. On the basis of in-depth study of the 
role and mechanism of RA and RA-like substance in the 
prevention and treatment of tumor, the application of 
all-trans retinoic acid (ATRA) in the treatment of acute 
promyelocytic leukemia (APL) has increased the complete 
remission rate to 87%92% according to the latest data, 
showing a promising prospect in tumor treatment and a new 
way created of leukemia therapy. APL is the first human 
malignant tumor cured for its tumor-specific biological be-
havior. More than 95% of APL patients have the character-
istic non-random chromosome t (15; 17). The translocation 
helps promyelocytic leukemia (PML) gene on chromosome 
15 to be fused with the retinoic acid receptor α (RAR-α) 
gene on chromosome 17. The expression of the PML-RAR 
fusion protein is crucial to the mechanism of differentiation 
block and onset of APL. Targeting against this, all-trans 
retinoic acid may dismiss the differentiation block effect of 
PML-RAR protein and propel differentiation of leukemia 
cells to normal cells. 
2.2  Inhibition of abnormal oncogenic signaling of tu-
mor cells to suppress tumor growth and let the patient 
“live with tumor” 
Abnormal activation of oncogenes is a main propeller in 
tumor development, and decrease of its power will delay 
tumor progression. Chronic myelogenous leukemia (CML) 
is characterized by Philadelphia chromosome (Ph+) with 
more than 90% of all CML cases have the marker chromo-
some-Ph+ chromosome. Molecular basis for this disease is 
that the translocation between the abl gene on chromosome 
9 and the bcr gene on chromosome 22 forms bcr/abl fusion 
gene which expresses the bcr-abl fusion protein-tyrosine 
kinase. Imatinib mesylate (Gleevec) is a tyrosine kinase 
inhibitor selectively inhibiting the tyrosine kinase produced 
by bcr/abl fusion gene. As the first human tyrosine kinase 
inhibitor, Gleevec is very effective in treating CML and the 
CR rate for newly diagnosed Ph+ ALL is up to 95%. 
Imatinib is important in history because its emergence veri-
fied the “oncogene” hypothesis. Under the guidance of this 
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drug-developing strategy, many tyrosine kinase inhibitors 
for different receptors, including EGFR, Her2, PDGFR, 
have been developed. Among them, trastuzumab (Her-
ceptin), a specific Her2 antibody, is another outstanding 
drug proving once again that “oncogene” is very important 
in the occurrence and development of solid tumors as well. 
Her2/neu (erb-B-2), expressed in 20%30% of metastatic 
breast cancer, predicts poor prognosis. After trastuzumab 
binds with the receptor, the corresponding receptor tyrosine 
kinase signaling will be blocked, thus inhibiting tumor cell 
growth and tumor angiogenesis and increasing tumor cell 
sensitivity to apoptosis signals. The antibody-dependent 
cytotoxicity (ADCC) may also be one of the mechanisms by 
which trastuzumab works. 
No matter trastuzumab is used as monotherapy or in 
combined chemotherapy, this drug can significantly inhibit 
the development of breast cancer with high Her2 expression 
(+++++). More importantly, a number of studies have 
confirmed that trastuzumab used as adjuvant therapy can 
significantly reduce tumor recurrence and mortality rate in 
Her2-positive patients. 
2.3  Enhancing anti-tumor effect with both intervention 
on tumor stroma and inhibition of tumor cells acting 
together 
Tumor stroma is composed of normal cells and their prod-
ucts. The genome of stromal cells is stable and it is not so 
easy for them to develop drug-resistance, making them one 
of the ideal targets of anti-tumor therapy. Although as early 
as 1974, Folkman proposed to inhibit tumor growth by in-
hibiting tumor angiogenesis, the idea of anti-angiogenisis 
was not accepted by the public until 1997 when endostatin, 
a specific inhibitor of angiogenesis, was found. In the year 
of 2004 a VEGF-specific monoclonal antibody bevaci-
zumab came into market, demonstrating anti-angiogenesis 
strategy was finally turned into reality. Clinical studies have 
shown that only inhibition of tumor angiogenesis itself 
doesn’t have strong tumor-inhibitory effect, suggesting tu-
mor cells are in dominant position compared with neovas-
cularization. So a two-phase treatment strategy to inhibit 
both tumor cells and tumor blood vessels was developed. 
Tumor angiogenesis inhibitors have proved that tumor 
stroma plays an important role in the tumor development 
and interference with tumor stroma is an important com-
plement to the strategy of directly suppression of tumor 
cells. In the near future, the tumor interstitial matrix or other 
cells in the stroma such as lymphocytes, macrophages, and 
fibroblasts are likely to become targets for treatment.  
2.4  Application of the immunological characteristics of 
antibody in specifically killing tumor cells 
The specific binding of antibody and antigen lays basis for a 
highly selective treatment. A number of clinical trials have 
proven that rituximab, a CD20-specific antibody, when used 
in combined chemotherapy, can significantly improve the 
prognosis of diffuse large B cell lymphoma and low-grade 
follicular malignant lymphoma. CD20 is a lineage marker 
instead of an “oncogene”. The success of rituximab shows 
that with the guidance of lineage marker, monoclonal anti-
bodies may make use of the immunological characteristics 
of antibody, such as ADCC and complement-dependent 
cytotoxicity to inhibit tumor growth. Based on the guiding 
role of antibodies, radiation immunology has been devel-
oped and several monoclonal antibodies used in radiation 
for lymphoma, liver cancer, lung cancer have already come 
into market.  
3  Problems and trends of molecular targeted 
therapy  
3.1  Looking for targets more specific to tumor cells  
At present, the nature of tumor is still not clear. Onco-
genes/tumor suppressor genes control the occurrence and 
development of malignant tumors, but they are also in-
volved in important physiological activities. How to moder-
ately interfere with these oncogenic signaling remains a 
huge challenge. In recent years, a cancer stem cell hypothe-
sis provides us with new understanding for the mechanism 
of occurrence, development and metastasis of malignant 
tumors. It now appears that the vast majority of tumor cells 
in most types of malignant tumors have a certain degree of 
sensitivity to conventional treatments such as radiotherapy 
and chemotherapy, only a small number of tumor cells have 
superb self-replicate ability and the ability to pump out 
chemotherapy drugs and thus developing drug resistance. 
Such cells are called cancer stem cells. The first studies in 
hematology have confirmed that not only the existence of 
cancer stem cells is a cause for the resistance, recurrence 
and metastasis, but also malignant transformation of stem 
cells at different stages is a cause for tumor occurrence. Our 
laboratory has recently isolated some tumor cells with phe-
notypic characteristics of stem cells from nasopharyngeal 
carcinoma, and confirmed that these cells do have abilities 
of anti-radiation, developing drug-resistance and metastasis 
much stronger than other tumor cells. Are these tumor cells 
with phenotypic characteristics of stem cells a manifestation 
of heterogeneity in tumor cells? We all know that loss of 
genomic stability is an essential feature of tumor cells, and 
that it will lead to a high degree of heterogeneity in tumor 
cells. So when we examine tumor cells in the pathological 
slices, we can see a great variety in the number of chromo-
somes and a high frequency of chromosome fragment loss 
and amplification without much regularity. In view of this, 
we must think about (i) how to develop drugs more focused 
and targeting those tumor cells with the phenotype of stem 
cells; (ii) we should be more careful in the use of cytotoxic 
drugs with impact on genomic stability.  
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3.2  Individualized therapy under the guidance of  
molecular markers to improve the effectiveness of 
treatment 
Malignant tumors are of high heterogeneity at the molecular 
level. Loss of tumor genomic instability will make tumor 
cells evolve in unpredictable directions. The present theory 
from evidence-based medicine neglects the heterogeneity of 
tumor cells. It is of much blindness to treat individual pa-
tients under the guidance of prognosis of groups of patients 
and the value of molecular targeted therapy is also largely 
underestimated. With the help of chip technology and bio-
informatics technology, we can accurately classify tumor 
cells in the level of gene structure and expression level 
(molecular typing) and use the information to guide treat-
ment. The Cancer Center of Sun Yat-sen University has 
conducted a preliminary exploration in this area. As tumor 
development has multi-gene in participation and multi-step 
in progress, it is necessary to use multi-target combined 
treatment and multi-target sequential therapy in achieving 
the goal of “living with tumor”. In the future it is possible to 
determine genome-widely one or several abnormal genetic 
signaling indispensable to tumor cells in some stage during 
the development of disease, for which accurate treatment 
can be used for the identified target. On the basis of “treat-
ment according to the identified target” and heterogeneity of 
tumors, we can achieve “treating the apparently same dis-
eases with different methods and treating apparently differ-
ent diseases with the same method”—an old saying from 
Chinese Medicine describing excellent therapeutics.  
In addition to “treatment according to the identified tar-
get”, another key in elevating treatment accuracy is to 
maximize the biological effects of targeted drugs. Molecular 
targeted drugs are non-cytotoxic with prominent individual 
differences in their tolerability and plasma concentration. It 
is difficult to find a most appropriate effective dose between 
the lowest effective dose and the highest tolerated dose by 
conventional clinical trials. So it is necessary to undertake 
"individualized titration" in the course of treatment based on 
targets related biological response markers to maximize the 
efficacy of molecular targeted drugs. 
A decade of efforts in pursuing our dream now seems 
only a flash passed. Clinical practice has proved that the 
molecular targeted therapy is a young and dynamic treat-
ment strategy and drug treatment for malignant tumors is 
undergoing a process from quantitative change to qualita-
tive change. For chemotherapy-sensitive tumors, molecular 
targeted therapy combined with traditional therapeutic 
means is able to further improve the prognosis of patients. 
For tumors insensitive to chemotherapy, molecular targeted 
therapy will gradually replace the chemotherapy and bring 
in the upcoming “post-chemotherapy era” in the near future. 
It is a pride for us Chinese people that in this great historical 
change. The contribution of Chinese scientists is really no-
ticeable. Drs. Wang ZhenYi and Chen Zhu have been inter-
nationally recognized as the finder of the trans-retinoic ac-
id-induced differentiation of leukemia cells. Dr. Luo 
YongZhang developed modified endostatin (Endostar). Dr. 
Chen ZhiNan developed a monoclonal antibody for liver 
cancer’s radioimmunotherapy. Dr. Peng ZhaoHui carried 
out industrialization of the first gene therapy drug-recom- 
binant human p53 adenovirus injection. Very recently, a 
small molecular drug, Conmana, was successfully devel-
oped by a Chinese company for targeted therapy for late- 
stage lung cancer patients. These achievements have con-
tributed to the development of tumor molecular targeted 
therapy. 
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